BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 9084455)

  • 1. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma.
    Amantea MA; Forrest A; Northfelt DW; Mamelok R
    Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma.
    Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W
    Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
    Coukell AJ; Spencer CM
    Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AIDS-related Kaposi's sarcoma: a phase II study of liposomal doxorubicin. The TLC D-99 Study Group.
    Cheung TW; Remick SC; Azarnia N; Proper JA; Barrueco JR; Dezube BJ
    Clin Cancer Res; 1999 Nov; 5(11):3432-7. PubMed ID: 10589755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma.
    Northfelt DW; Martin FJ; Working P; Volberding PA; Russell J; Newman M; Amantea MA; Kaplan LD
    J Clin Pharmacol; 1996 Jan; 36(1):55-63. PubMed ID: 8932544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
    Northfelt DW; Dezube BJ; Thommes JA; Levine R; Von Roenn JH; Dosik GM; Rios A; Krown SE; DuMond C; Mamelok RD
    J Clin Oncol; 1997 Feb; 15(2):653-9. PubMed ID: 9053490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
    Hernández-Morales DE; Hernández-Zaccaro AE
    Eur J Cancer Care (Engl); 2005 Jul; 14(3):264-6. PubMed ID: 15952971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial.
    Northfelt DW; Dezube BJ; Thommes JA; Miller BJ; Fischl MA; Friedman-Kien A; Kaplan LD; Du Mond C; Mamelok RD; Henry DH
    J Clin Oncol; 1998 Jul; 16(7):2445-51. PubMed ID: 9667262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal doxorubicin: new preparation. Useful in Kaposi's sarcoma.
    Prescrire Int; 1998 Jun; 7(35):69-70. PubMed ID: 10342919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma.
    Gill PS; Mitsuyasu RT; Montgomery T; Huang J; Cabriales S; Testa M; Espina BM; Levine AM; Miles SA
    Cancer J Sci Am; 1997; 3(5):278-83. PubMed ID: 9327151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin.
    Gabizon A; Isacson R; Rosengarten O; Tzemach D; Shmeeda H; Sapir R
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):695-702. PubMed ID: 17549475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma.
    Gill PS; Lunardi-Ishkandar Y; Louie S; Tulpule A; Zheng T; Espina BM; Besnier JM; Hermans P; Levine AM; Bryant JL; Gallo RC
    N Engl J Med; 1996 Oct; 335(17):1261-9. PubMed ID: 8857005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter phase II study of the intravenous administration of liposomal tretinoin in patients with acquired immunodeficiency syndrome-associated Kaposi's sarcoma.
    Bernstein ZP; Chanan-Khan A; Miller KC; Northfelt DW; Lopez-Berestein G; Gill PS
    Cancer; 2002 Dec; 95(12):2555-61. PubMed ID: 12467070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients.
    La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
    Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
    Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
    Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
    Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disseminated classic Kaposi's sarcoma. Two cases with excellent response to pegylated liposomal doxorubicin.
    Castiñeiras I; Almagro M; Rodríguez-Lozano J; Fernández-Jorge B; Paradela S; Pozo JD; Fonseca E
    J Dermatolog Treat; 2006; 17(6):377-80. PubMed ID: 17853313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy and alpha-interferon in the treatment of Kaposi's sarcoma associated with acquired immune deficiency syndrome.
    Shepherd FA; Evans WK; Garvey B; Read SE; Klein M; Fanning MM; Coates R
    CMAJ; 1988 Oct; 139(7):635-9. PubMed ID: 2458177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.